Denali Therapeutics Inc.

Denali Therapeutics Misses on EPS, Stock Down 1.69%

Denali Therapeutics reported a loss per share that was slightly worse than expected, which contributed to a 1.69% decline in stock price. The absence of revenue figures and guidance may raise concerns among investors about the company's financial health and future prospects. The focus on pipeline development suggests that management is prioritizing long-term goals over short-term financial performance.